HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has maintained a Buy rating on InflaRx (NASDAQ:IFRX) but has reduced the price target from $9 to $8.
January 25, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
InflaRx's stock may experience a mixed short-term impact due to the maintained Buy rating but lowered price target from $9 to $8 by HC Wainwright & Co.
While the maintained Buy rating suggests continued confidence in InflaRx's potential, the lowered price target could indicate a tempered expectation for the stock's performance. Investors may view the price target cut as a negative signal, potentially offsetting the positive sentiment from the Buy rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100